| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Molecular Diagnostics & Therapeutics, Inc. |
| 1880 Industrial Circle, Suite B-3, Longmont, CO 80501 * (303) 485-8500 |
| Business Description | The company plans to manufacture, market and distribute a range of radiopharmaceuticals and radiochemicals to the nuclear medicine industry, an endeavor that represents the merger of medicine and biology. |
|
Filing Information Not yet | |||
| To Trade As | - - (NASSCM) | Industry | Pharmaceutical (SIC 2835) |
| Type of Stock Offered | Common Shares | Filing Date | 3/31/00 |
| Domestic Shares Filed | 1,000,000 | Filing Price | $10.00 |
| Foreign Shares Filed | 0 | Offering Amount | $10,000,000 |
| Company Shares | 1,000,000 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Three Arrows Capital Corp. | Lead Manager | |
| Travis Morgan Securities, Inc. | Co-manager |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 9 Months Ending | ||||||
| Figures in U.S. millions except per share data | 3/31/98 | 3/31/99 | 12/31/98 | 12/31/99 | |||
| Revenues | - | - | - | 0.000 | 0.000 | 0.000 | 0.000 |
| Income from Oper. | - | - | - | - | - | - | - |
| Net Income | - | - | - | -0.277 | -0.752 | -0.382 | -0.509 |
| E.P.S | - | - | - | -0.040 | -0.100 | -0.050 | -0.060 |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -0.24 | -0.40 | -0.18 | ||||
| Cash Flow - Inv. | -0.02 | 0.00 | -0.01 | ||||
| Cash Flow - Fin. | 0.41 | 0.45 | 0.08 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 0.07 | Current Assets | - | Current Ratio | - |
| Total Liab. | 0.02 | Current Liab. | 0.02 | Debt Ratio | 25.66% |
| Total Equity | 0.05 | Working Cap. | - | Debt to Equity Ratio | 0.35 |
| Cash | 0.04 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for deposit on a building, purchase of equipment for the plant, working capital and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Reinhart, Boerner, Van Deuren, Norris & Rieselbach |
| Registrar/Transfer Agent | Self Administered |
| Auditor | Cordovano and Harvey, P.C. |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| First Trust Corporation | 5.90 | |
| Note: represents ownership of 5% or more prior to the offering. | ||